Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
Clinical trial NCT06987734 · RECRUITING
Trial details
- NCT number
- NCT06987734
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-19
- Primary completion
- 2027-12-31
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.